Medications and their effects on sleep

Medical Clinics of North America

Volumn 88, Issue 3, 2004, Pages 751-766

  Qureshi, Asher ^a   Lee Chiong Jr , Teofilo ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTIPARKINSON AGENT; ANTITUSSIVE AGENT; CAFFEINE; CARDIOVASCULAR AGENT; CENTRAL STIMULANT AGENT; CLOZAPINE; CORTICOSTEROID; DECONGESTIVE AGENT; HERBACEOUS AGENT; HYPNOTIC SEDATIVE AGENT; LITHIUM; MELATONIN; MONOAMINE OXIDASE INHIBITOR; MUSCLE RELAXANT AGENT; NEUROLEPTIC AGENT; NICOTINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN UPTAKE INHIBITOR; OPIATE; SEROTONIN UPTAKE INHIBITOR; SUMATRIPTAN; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ALLERGY; AMNESIA; ANXIETY DISORDER; APPETITE DISORDER; BEHAVIOR DISORDER; BIPOLAR DISORDER; BRAIN REGION; BRAIN STEM; COGNITIVE DEFECT; COMMON COLD; CONFUSION; DEPRESSION; DROWSINESS; DRUG DEPENDENCE; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG INTOXICATION; DRUG MECHANISM; DRUG TOLERANCE; EXTRAPYRAMIDAL SYMPTOM; EYE MOVEMENT DISORDER; FATIGUE; HALLUCINATION; HUMAN; INSOMNIA; NERVE PROJECTION; NERVOUSNESS; NEUROCHEMISTRY; NIGHTMARE; NONREM SLEEP; PARASOMNIA; PERSONALITY DISORDER; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; PSYCHOSIS; REM SLEEP; RESPIRATORY TRACT DISEASE; RESTLESS LEGS SYNDROME; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SLEEP; SLEEP DISORDER; SOMNOLENCE; TARDIVE DYSKINESIA; WAKEFULNESS;

ANTICONVULSANTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; DISORDERS OF EXCESSIVE SOMNOLENCE; ETHANOL; HUMANS; HYPNOTICS AND SEDATIVES; MONOAMINE OXIDASE INHIBITORS; NARCOTICS; NICOTINE; SEROTONIN UPTAKE INHIBITORS; SLEEP DISORDERS; SLEEP, REM; VITAMIN A;

EID: 1842829096     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2004.01.007     Document Type: Review

References (77)

1. Jones B.E. Basic mechanisms of sleep-wake states. Kryger M.H., Roth T., Dement W.C. Principles and practice of sleep medicine. 3rd edition:2000;134-154 WB Saunders, Philadelphia.
2. Morruzi G., Magoun H.W. Brainstem reticular formation and activation of the EEG. Electroencephalogr Clin Neurophysiol. 1:1949;455.
3. Dempsey E.W., Morison R.S., Morison B.R. Some afferent diencephalic pathways related to cortical potentials in the cat. Am J Physiol. 131:1941;718.
4. Kievet J., Kuypers H.G.J.M. Basal forebrain and hypothalamic connections to frontal and parietal cortex in the rhesus monkey. Science. 187:1975;660.
5. Steriade M. Mechanisms underlying cortical activation: neuronal organization and properties of the midbrain reticular core and intralaminar thalamic nuclei. Pompeiano O., Ajmone Marsan C. Brain mechanism and perceptual awareness. 1981;327 Raven Press, New York.
6. Plum F., Posner J.B. The diagnosis of stupor and coma. 1980;FA Davis, Philadelphia.
7. Feldman S.M., Waller H.J. Dissociation of electrocortical activation and behavioral arousal. Nature. 196:1962;1320.
8. Jouvet M. The role of monoamines and acetylcholine containing neurons in the regulation of the sleep-waking cycle. Ergeb Physiol. 64:1972;165.
9. Monnier M., Sauer R., Hatt A.M. The activating effect of histamine on the central nervous system. Int Rev Neurobiol. 12:1970;265.
10. Jasper H.H., Khan R.T., Elliott K.A.C. Amino acids released from the cerebral cortex in relation to its state of activation. Science. 147:1965;1488.
11. Norgren R. Projections from the nucleus of the solitary tract in the rat. Neuroscience. 3:1978;207.
12. Sterman M.B., Clemente C.D. Forebrain inhibitory mechanisms: sleep patterns induced by the basal forebrain stimulation in the behaving cat. Exp Neurol. 6:1962;103.
13. Hess W.R. The functional organization of the diencephalons. 1957;Grune & Stratton, New York.
14. Mugnaini E., Oertel W.H. An atlas of the distribution of GABAergic neurons and terminals. Bjorklund A., Hokfelt T. Handbook of chemical neuroanatomy, vol. 4. GABA and neuropeptides in the CNS, Part 1. 1985;436 Elsevier, Amsterdam, The Netherlands.
15. Radulovacki M., Virus R.M., Djuricic-Nedelson M., et al. Adenosine and adenosine analogs: effects on sleep in rats. McGinty D.J., Morrison A., Drucker-Colin R., et al. Brain mechanisms of sleep. 1985;235 Raven Press, New York.
16. Siegel J.M. Brainstem mechanisms generating REM sleep. Kryger M.H., Roth T., Dement W.C. Principles and practice of sleep medicine. 3rd edition:2000;112-133 WB Saunders, Philadelphia.
17. Shneerson J.M. Physiological basis of sleep and wakefulness. Schneerson J.M. Handbook of sleep medicine. 2000;16-32 Blackwell Science, Malden, MA.
18. Steriade M., Pare D., Parent A., Smith Y. Projections of cholinergic and non-cholenergic neurons of the brainstem core to relay and associational thalamic nuclei in the cat and macaque monkey. Neuroscience. 25:1988;47.
19. Schweitzer P.K. Drugs that disturb sleep and wakefulness. Kryger M.H., Roth T., Dement W.C. Principles and practice of sleep medicine. 3rd edition:2000;441-461 WB Saunders, Philadelphia.
20. Physicians Desk Reference. 57th edition:2003;Medical Economics Company, Montville, NJ.
21. Feighner J. Mechanism of action of antidepressant medications. J Clin Psychiatry. 60:1999;4-11.
22. Van Laar M.W., van Willigenburg A.P.P., Volkerts E.R. Acute and sub acute effects of nefazodone and imipramine on highway driving, cognitive functions and daytime sleepiness in healthy adult and elderly subjects. J Clin Psychopharmacol. 15:1995;30-40.
23. Kupfer D.J., Bowers M.B. Jr. REM sleep and central monoamine oxidase inhibition. Psychopharmacologia. 27:1972;183-190.
24. Rickles K., Schweizer E. Clinical overview of serotonin reuptake inhibitors. J Clin Psychiatry. 51:1990;9-12.
25. Haria M., Fitton A., McTavish D. Trazodone: a review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging. 4:1994;331-355.
26. Robinson D.S., Roberts D.L., Smith J.M., Stringfellow J.C., Kaplita S.B., Seminara J.A., et al. The safety profile of nefazodone. J Clin Psychiatry. 57:1996;31-38.
27. Salin-Pascual R.J., Galicia-Polo L., Drucker-Colin R. Sleep changes after 4 consecutive days of venlafaxine administration in normal volunteers. J Clin Psychiatry. 58:1997;348-350.
28. Luthringer R., Toussaint M., Schaltenbrand N., Bailey P., Danjou P.H., Hackett D., et al. A double blind, placebo controlled evaluation of the effects of orally administered venlafaxine on sleep in inpatients with major depression. Psychopharmacol Bull. 32:1996;637-646.
29. Nutt D. Mirtazapine: pharmacology in relation to adverse effects. Acta Psychiatr Scand Suppl. 391:1997;31-37.
30. Eisen J., MacFarlane J., Shapiro C.M. Psychotropic drugs and sleep: ABC of sleep disorders. BMJ. 306:1993;1331-1334.
31. Casey D.E. The relationship of pharmacology to side effects. J Clin Psychiatry. 58:1997;55-62.
32. Gerlach J., Peacock L. New antipsychotics: the present status. Int Clin Psychopharmacol. 10:1995;39-48.
33. Guilleminault C. Benzodiazepines, breathing and sleep. Am J Med. 88:1990;25S-28S.
34. Schnabel T. Evaluation of the safety and side effects of anti anxiety agents. Am J Med. 82:1987;7-13.
35. Seidel W.F., Cohen S.A., Wilson L., Dement W.C. Effects of alprazolam and diazepam on the daytime sleepiness of non-anxious adult subjects. Psychopharmacology. 87:1985;194-197.
36. Obermeyer W., Benca R. Effects of drugs on sleep. Neurol Clin. 14:1996;827-840.
37. Shneerson J.M. Drugs and sleep. Schneerson J.M. Handbook of sleep medicine. 2000;33-58 Blackwell Science, Malden, MA.
38. Nausieda P.A., Weiner W.J., Kaplan L.R., Weber S., Klawans H.L. Sleep disruption in the course of chronic levodopa therapy: an early feature of levodopa psychosis. Clin Neuropharmacol. 5:1982;183-194.
39. Cooper J.A., Sagar H.J., Dohertty S.M., Jordan N., Tidswell P., Sullivan E.V. Different effects of dopaminergic and anticholinergics therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients. Brain. 115:1992;1701-1725.
40. Cumming J.L. Behavioral complications of drug treatment of Parkinson's disease. J Am Geriatr Soc. 39:1991;708-716.
41. Sammaritano M., Sherwin A. Effects of anticonvulsants on sleep. Neurology. 54:2000;S16-S24.
42. American Academy of Pediatrics. Behavioral and cognitive effects of anticonvulsant therapy. Committee on drugs. Pediatrics. 76:1985;644-647.
43. Ferrendelli J.A. Pharmacology of antiepileptic drugs. Epilepsia. 28:1987;S14-S16.
44. Brodie M.J., Dichter M.A. Established antiepileptic drugs. Seizure. 6:1997;159-174.
45. Rogvi-Hansen B., Gram L. Adverse effects of established and new antiepileptic drugs: an attempted comparison. Pharmacol Ther. 68:1995;425-434.
46. Donnelly F., Rihoux J.P., DeVos C. Sedative effects of antihistamines: safety, performance, learning and quality of life. Clin Ther. 20:1998;365-372.
47. Roth T., Roehrs T., Koshorek G., Sicklesteel J., Zorick F. Sedative effects of antihistamines. J Allergy Clin Immunol. 80:1987;94-98.
48. Ramaekers G.J., Uiterwijk M.M., O'Hanlon J.F. Effects of loratadine and cetirizine on actual driving and psychometric test performance, and EEG during driving. Eur J Clin Pharmacol. 42:1992;363-369.
49. Berlin R.G. Effects of H2-receptor antagonists on the central nervous system. Drug Dev Res. 17:1989;97-108.
50. Lipsy R.J., Fennerty B., Fagan T. Clinical review of histamine 2 receptor antagonists. Arch Intern Med. 150:1990;745-751.
51. Schentag J.J. Cimetidine associated mental confusion: further studies in 36 severely ill patients. Ther Drug Monit. 78:1980;791-795.
52. Gleiter C.H., Deckert J. Adverse CNS effects of beta adrenoceptor blockers. Pharmacopsychiatry. 29:1996;201-211.
53. Paykel E.S., Fleminger R., Watson J.P. Psychiatric side effects of antihypertensive drugs other than reserpine. J Clin Psychopharmacol. 2:1982;14-39.
54. Webster J., Koch H.F. Aspects of tolerability of centrally acting antihypertensive drugs. J Cardiovasc Pharmacol. 27:1996;S49-S54.
55. Pearce C.J., Wallin J.D. Labetalol and other agents that block both alpha and beta adrenergic receptors. Cleve Clin J Med. 61:1994;59-69.
56. Monti J. Minireview: disturbances of sleep and wakefulness associated with the use of antihypertensive agents. Life Sci. 41:1987;1979-1988.
57. Wesnes K., Simpson P.M., Jansson B., Grahnen A., Weimann H.J., Kuppers H. Moxonidine and cognitive function: interactions with moclobemide and lorazepam. Eur J Clin Pharmacol. 52:1997;351-358.
58. Kuyer W.B., Hickman J.R. Jr. Medication induced performance decrements: cardiovascular medications. J Occup Med. 32:1990;342-349.
59. Michelson E.L., Dreifus L.S. Newer antiarrhythmic drugs: cardiovascular pharmacotherapy II. Med Clin North Am. 72:1988;275-319.
60. Idzikowski C., Shapiro C. Non psychotropic drugs and sleep: ABC of sleep disorders. BMJ. 306:1993;1118-1121.
61. Strading J.R. Recreational drugs and sleep: ABC of sleep disorders. BMJ. 306:1993;575-576.
62. Zhdanova I.V., Lynch H.J., Wurtman R.J. Melatonin: a sleep-promoting hormone. Sleep. 20:1997;899-907.
63. Post R.M., Gillin J.C., Wyatt R.J., Goodwin F.K. The effect of orally administered cocaine on sleep of depressed patients. Psychopharmacology (Berl). 37:1974;59.
64. Buguet A., Montmayeur A., Pigeau R., Naithoh P. Modafinil, d-amphetamine and placebo during 64 hours of sustained mental work II. Effects on two nights of recovery sleep. J Sleep Res. 4:1995;229-241.
65. Roehrs T., Merlotti L., Halpin D., Rosenthal L., Roth T. Effects of theophylline on nocturnal sleep and daytime sleepiness/alertness. Chest. 108:1995;382-387.
66. Wiegand L., Mende C.N., Zaidel G., Zwillich C.W., Petrocella V.J., Yancey S.W., et al. Salmeterol vs theophylline: sleep and efficacy outcomes in patients with nocturnal asthma. Chest. 115:1999;1525-1532.
67. Bech P., Ciadella P. Citalopram in depression: meta-analysis of intended and unintended effects. Clin Psychopharmacol. 6:1992;45-54.
68. Nofzinger E.A., Reynolds C.F. III, Thase M.E., Frank E., Jennings J.R., Fasiczka A.L., et al. REM sleep enhancement by bupropion in depressed men. Am J Psychiatry. 152:1995;274-276.
69. Gillin J.C. The long and the short of sleeping pills. N Engl J Med. 324:1991;1735-1736.
70. Kostis J.B., Rosen R.B., Wilson A.C. Central nervous system effects of HMG Co A reductase on sleep and cognitive performance in patients with hypercholesterolemia. J Clin Pharmacol. 34:1994;989-996.
71. Roth T., Richardson G.R., Sullivan J.P., Lee R.M., Merlotti L., Roehrs T. Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance. Clin Cardiol. 15:1992;426-432.
72. Empey D.W., Medder K.T. Nasal decongestants. Drugs. 21:1981;438-443.
73. Rombaut N.E.I., Alford C., Hindmarch I. Effects of oral administration of different formulations of pseudoephedrine on day and night-time CNS activity. Med Sci Res. 17:1989;831-833.
74. Wiegand M., Bossert S., Kinney R., Pirke K.M., Krieg J.C. Effect of dexfenfluramine on sleep in healthy subjects. Psychopharmacology (Berl). 105:1991;213-218.
75. Mahowald M.W., Schenk C.H. REM sleep parasomnias. Kryger M.H., Roth T., Dement W.C. Principles and practice of sleep medicine. 3rd edition:2000;724-743 WB Saunders, Philadelphia.
76. Novak M., Shapiro C.M. Drug induced sleep disturbances. Drug Saf. 16:1997;133-148.
77. Cooper G.L. The safety of fluoxetine: an update. Br J Psychiatry. 153:1988;77-86.